Compare OMH & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMH | SNGX |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | Singapore | United States |
| Employees | N/A | 14 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 8.2M |
| IPO Year | 2022 | 2006 |
| Metric | OMH | SNGX |
|---|---|---|
| Price | $2.36 | $0.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 27.4M | 243.1K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $119,371.00 |
| Revenue This Year | $28.40 | N/A |
| Revenue Next Year | $23.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $0.28 |
| 52 Week High | $3.75 | $2.57 |
| Indicator | OMH | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 63.50 | 49.47 |
| Support Level | $0.91 | $0.37 |
| Resistance Level | $3.75 | $0.38 |
| Average True Range (ATR) | 0.29 | 0.02 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 18.82 | 45.33 |
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, Digital Marketing Services, and emerging and other services. The firm operates in two segments, which are Brokerage, emerging and another related service; and Estate management services and other related services in Singapore.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).